Cagrilintide is not approved in any country. That is not a vague legal status — it is a clear fact: it appears on no regulator's approved list.
That does not mean cagrilintide is absent from the market. It means the portion in circulation has no legal pathway.
[The FDA's unequivocal position]
The FDA's September 1, 2026 statement on unapproved GLP-1 drugs includes one direct sentence: "Retatrutide and cagrilintide cannot be used in compounding under federal law." [citation:14]
Neither drug is a component of any approved medicine, and neither has been found safe and effective for any condition. This differs from semaglutide, which was permitted to be compounded during shortages. Cagrilintide has no such window.
[CagriSema is under review, but that is not cagrilintide alone]
Novo Nordisk submitted an NDA to the FDA on December 18, 2025 for CagriSema — a fixed-dose combination of cagrilintide and semaglutide — based on REDEFINE 1 and REDEFINE 2 data [citation:6]. A decision is expected in 2026.
If approved, cagrilintide would be available only as a component of that combination, delivered via injection pen. Novo Nordisk has no plan for a standalone cagrilintide product.
[The March 2026 warning letters]
On March 31, 2026, the FDA issued warning letters to multiple online peptide vendors whose listings included cagrilintide [citation:1][citation:10].
The FDA's reasoning was not about labels. The letter states directly: "Despite statements on your product labeling marketing your products for 'laboratory research purposes only' and 'not for human consumption, medical use or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use." [citation:1]
The evidence the FDA cited included website descriptions of weight-loss effects, mechanism-of-action explanations, and statements that the "research peptide" has "potential in diabetes management and obesity treatment." [citation:1]
[Why "research use only" labels don't work]
The FDA determines "intended use" not from disclaimers on the label, but from the objective intent of the party responsible for labeling and marketing [citation:13].
Specifically, the FDA looks at:
- User testimonials on the website
- Dosing information
- Marketing content
- Whether the product is sold alongside injection supplies
A detail the FDA repeatedly cited in 2026 warning letters: vendors selling cagrilintide alongside bacteriostatic water. The FDA's logic is that bacteriostatic water is used to dilute or reconstitute injectable drugs, so selling them together demonstrates the products are intended for injection — making the bacteriostatic water itself a drug [citation:3][citation:13].
[Enforcement targets sellers, not buyers]
This has been consistent across the peptide crackdown. In March 2026, Cincinnati CBP seized roughly 5,000 undeclared peptide shipments from China, including retatrutide, semaglutide, tirzepatide and cagrilintide [citation:8].
On April 1, 2026, a Utah grand jury indicted a licensed physician for introducing unapproved peptides, including cagrilintide, into interstate commerce [citation:4].
In Q1 2026 alone, the FDA issued 41 warning letters, and Peptide Sciences — one of the industry's largest vendors — voluntarily shut down on March 6 [citation:18].
Enforcement targets sellers. But what arrives in the mail is an unapproved drug of unknown origin.
[If you are considering a purchase]
There is no legal individual purchase pathway for cagrilintide. No prescription form, no compounding exemption, no "research use" exception.
The "research use only" label protects the seller's wording, not the buyer's safety. The FDA has made clear it will look past the label at what the website actually says.
As for enforcement risk: buyers are not currently the primary target. But purity, dosing and sterility carry no guarantees, and those risks sit with the purchaser.